These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 33301128

  • 1. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K, Oak ASW, Elewski BE.
    Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ.
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [Abstract] [Full Text] [Related]

  • 3. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
    Boehncke WH, Brembilla NC, Nissen MJ.
    Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
    [Abstract] [Full Text] [Related]

  • 4. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J, Goldenberg G.
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
    Johnsson HJ, McInnes IB.
    Clin Exp Rheumatol; 2015 Feb; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
    [Abstract] [Full Text] [Related]

  • 6. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [Abstract] [Full Text] [Related]

  • 7. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
    Alunno A, Carubbi F, Cafaro G, Pucci G, Battista F, Bartoloni E, Giacomelli R, Schillaci G, Gerli R.
    Expert Opin Biol Ther; 2015 Jul; 15(12):1727-37. PubMed ID: 26653110
    [Abstract] [Full Text] [Related]

  • 8. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A, Ulschmid C, Gordon KB.
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [Abstract] [Full Text] [Related]

  • 9. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2247-2259. PubMed ID: 28825875
    [Abstract] [Full Text] [Related]

  • 10. A non-clinical comparative study of IL-23 antibodies in psoriasis.
    Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, Gauld S, Konrad M, Leys L, McCarthy R, Namovic M, Nelson C, Overmeyer G, Perron D, Su Z, Wang L, Westmoreland S, Zhang J, Zhu R, Veldman G.
    MAbs; 2021 Oct 03; 13(1):1964420. PubMed ID: 34460338
    [Abstract] [Full Text] [Related]

  • 11. Guselkumab for the Treatment of Psoriasis.
    Machado Á, Torres T.
    BioDrugs; 2018 Apr 03; 32(2):119-128. PubMed ID: 29470778
    [Abstract] [Full Text] [Related]

  • 12. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W.
    Br J Pharmacol; 2010 Jun 03; 160(4):810-20. PubMed ID: 20590580
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab for treating plaque psoriasis.
    Rothstein B, Gottlieb A.
    Expert Opin Biol Ther; 2016 Jun 03; 16(1):119-28. PubMed ID: 26577956
    [Abstract] [Full Text] [Related]

  • 14. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.
    Frleta M, Siebert S, McInnes IB.
    Curr Rheumatol Rep; 2014 Apr 03; 16(4):414. PubMed ID: 24570394
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
    J Dermatolog Treat; 2018 Sep 03; 29(6):569-578. PubMed ID: 29532693
    [Abstract] [Full Text] [Related]

  • 16. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E.
    Inflamm Allergy Drug Targets; 2012 Apr 03; 11(2):159-68. PubMed ID: 22280236
    [Abstract] [Full Text] [Related]

  • 17. The role of IL 23 in the treatment of psoriasis.
    Puig L.
    Expert Rev Clin Immunol; 2017 Jun 03; 13(6):525-534. PubMed ID: 28165883
    [Abstract] [Full Text] [Related]

  • 18. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
    Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG.
    Adv Ther; 2023 Aug 03; 40(8):3410-3433. PubMed ID: 37330926
    [Abstract] [Full Text] [Related]

  • 19. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W, Downing C, Tyring S.
    J Cutan Med Surg; 2014 Aug 03; 18(3):156-69. PubMed ID: 24800703
    [Abstract] [Full Text] [Related]

  • 20. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ, Triche MW, Espinoza LR.
    Expert Opin Biol Ther; 2018 Jul 03; 18(7):821-827. PubMed ID: 29949399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.